Didanosine 125 mg Delayed Release Oral Capsule
RxNorm 284183
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 284183 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: didanosine 125 mg Delayed Release Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCD
Semantic Clinical Drug (SCD):
Didanosine 125 mg Delayed Release Oral Capsule
(Atom ID: 12333010)
SY
Synonym (SY):
DdI 125 mg Delayed Release Oral Capsule
(Atom ID: 6339397)
PSN
Prescribable Name (PSN):
Didanosine 125 mg Delayed Release Oral Capsule
(Atom ID: 6362570)
PT
Designated preferred name (PT):
Didanosine 125 mg gastro-resistant oral capsule
(Atom ID: 10297247)
SY
Synonym (SY):
Dideoxyinosine 125 mg Delayed Release Oral Capsule
(Atom ID: 6339231)
FN
Full form of descriptor (FN):
Product containing precisely didanosine 125 mg/1 each gastro-resistant oral capsule (clinical drug)
(Atom ID: 10311439)
Patient Education
Didanosine
Didanosine is used along with other medications to treat human immunodeficiency virus (HIV) infection. Didanosine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV in the blood. Although didanosine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
[Learn More]
* Please review the disclaimer below.